Article metrics

Download PDFPDF

2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 2022119010
Nov 20229908
Dec 2022134022
Jan 202314207
Feb 202386013
Mar 202381010
Apr 20231705
May 20233408
Jun 20233704
Jul 20233707
Aug 20236509
Sep 20231606
Oct 20232003
Nov 202338011
Dec 20232305
Jan 20241402
Feb 20241200
Mar 20241608
Apr 20241804
May 20241802
Jun 202448011
Jul 20241007
Aug 20241906
Sep 20241704
Oct 2024801
Total11280173